Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6245MR)

This product GTTS-WQ6245MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6245MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15880MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ5484MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ13229MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ2672MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ8675MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ7839MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ13140MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7630MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW